Caligan Partners LP
CIK: 0001727492Latest portfolio: $1.2B · Q4 2025
Holdings
21
Total Value
$1.2B
New Positions
8
Closed Positions
4
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | LQDALIQUIDIA CORPORATION | 8,118,892 | $280.0M | 23.05% | — | |
| 2 | ABVXABIVAX SA | 1,451,924 | $195.8M | 16.12% | — | |
| 3 | MLYSMINERALYS THERAPEUTICS INC | 5,071,054 | $184.0M | 15.15% | NEW | Put |
| 4 | RVMDREVOLUTION MEDICINES INC | 1,283,900 | $102.3M | 8.42% | +220K | |
| 5 | PCVXVAXCYTE INC | 1,704,815 | $78.7M | 6.48% | NEW | |
| 6 | EX9EXELIXIS INC | 1,553,262 | $68.1M | 5.60% | +28K | |
| 7 | ADMAADMA BIOLOGICS INC | 3,012,508 | $54.9M | 4.52% | +376K | |
| 8 | XENEXENON PHARMACEUTICALS INC | 1,099,365 | $49.3M | 4.06% | NEW | Put |
| 9 | INBXINHIBRX BIOSCIENCES INC | 473,565 | $37.4M | 3.08% | NEW | Call |
| 10 | TNGXTANGO THERAPEUTICS INC | 3,729,895 | $33.0M | 2.72% | NEW | |
| 11 | TYRATYRA BIOSCIENCES INC | 944,257 | $24.8M | 2.04% | +247K | |
| 12 | MAZEMAZE THERAPEUTICS INC | 550,191 | $22.8M | 1.88% | NEW | |
| 13 | RAPTRAPT THERAPEUTICS INC | 644,400 | $21.8M | 1.80% | NEW | |
| 14 | AVTXAVALO THERAPEUTICS INC | 881,533 | $16.0M | 1.32% | +48K | |
| 15 | ANIKANIKA THERAPEUTICS INC | 1,435,130 | $13.8M | 1.14% | — | |
| 16 | VORVOR BIOPHARMA INC | 925,067 | $10.0M | 0.82% | NEW | |
| 17 | IVAINVENTIVA SA | 2,000,000 | $9.3M | 0.77% | NEW | |
| 18 | VRCAVERRICA PHARMACEUTICALS INC | 923,910 | $7.7M | 0.63% | — | |
| 19 | AGIOAGIOS PHARMACEUTICALS INC | 90,000 | $2.4M | 0.20% | NEW | Call |
| 20 | SPRBSPRUCE BIOSCIENCES INC | 20,514 | $1.8M | 0.15% | NEW | |
| 21 | ELDNELEDON PHARMACEUTICALS INC | 555,978 | $839K | 0.07% | NEW |
Quarterly Changes
New Positions
Sector Breakdown
Healthcare0.0% ($2.8002019579918402e+87T)
Unknown0.0% ($68.1M)
Filing History
Fund Information
Caligan Partners LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $1.2B across 21 holdings. The largest position is LIQUIDIA CORPORATION (LQDA), representing 23.1% of the portfolio. Compared to the previous quarter, the fund opened 12 new positions and closed 8 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.